Breast cancer screening in germline mutation carriers. A literature review

Cover Page

Cite item

Full Text

Abstract

Carriers of germline mutations have an increased risk of developing malignant neoplasms. Mutations in the BRCA1/2 gene are the most studied, leading to an increased risk of breast cancer, characterized by early manifestation and aggressive course. The development of screening measures aimed at identifying tumors characteristic of certain mutations will increase the patient’s chances for radical treatment, and therefore lower costs for the treatment of advanced forms of malignant neoplasms. It is important to know the correlation of mutations with the characteristics of their clinical manifestation, the study of this issue will lead to the formation of a medical and economic justification for additional diagnostic procedures.

About the authors

A. V. Sultanbaev

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan; Republican Center for Medical Genetics, Ministry of Health of the Republic of Bashkortostan

Author for correspondence.
Email: rkodrb@yandex.ru
ORCID iD: 0000-0003-0996-5995

Aleksandr V. Sultanbaev.

73/1 Prospekt Oktyabrya, Ufa 450054; 74 Gafuri St., Ufa 450076, Republic of Bashkortostan

Russian Federation

A. F. Nasretdinov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0001-8340-7962

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

M. G. Galeev

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0001-7277-4644

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

K. V. Menshikov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan; Republican Center for Medical Genetics, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0003-3734-2779

73/1 Prospekt Oktyabrya, Ufa 450054; 74 Gafuri St., Ufa 450076, Republic of Bashkortostan

Russian Federation

Sh. I. Musin

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0003-1185-977X

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

N. I. Sultanbaeva

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0001-5926-0446

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

R. T. Ayupov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-6769-7194

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

R. R. Rakhimov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-2488-597X

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

O. N. Lipatov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan; Bashkir State Medical University, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-8867-504X

73/1 Prospekt Oktyabrya, Ufa 450054; 3 Lenina St., Ufa 450008, Republic of Bashkortostan

Russian Federation

A. A. Izmaylov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan; Bashkir State Medical University, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-8461-9243

73/1 Prospekt Oktyabrya, Ufa 450054; 3 Lenina St., Ufa 450008, Republic of Bashkortostan

Russian Federation

I. A. Menshikova

Bashkir State Medical University, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-8665-8895

3 Lenina St., Ufa 450008, Republic of Bashkortostan

Russian Federation

G. A. Serebrennikov

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-7082-0085

73/1 Prospekt Oktyabrya, Ufa 450054

Russian Federation

D. O. Lipatov

Bashkir State Medical University, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-3193-9008

3 Lenina St., Ufa 450008, Republic of Bashkortostan

Russian Federation

References

  1. Sessa C., Balmaña J., Bober S.L. et al. ESMO Guidelines Committee. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes: ESMO Clinical Practice Guideline. Ann Oncol 2023;34(1):33–47. doi: 10.1016/j.annonc.2022.10.004
  2. Nikitin A.G., Brovkina O.I., Khodyrev D.S. et al. Creating a public mutation database oncoBRCA: bioinformatic problems and solutions. Klinicheskaya praktika = Clinical practice 2020;11(1):21–9. (In Russ.). doi: 10.17816/clinpract25860
  3. Imyanitov E.N. Advances in fundamental oncology: the year 2020 update. Prakticheskaya onkologiya = Practical oncology 2021;22(1):1–8. (In Russ.). doi: 10.31917/2201001
  4. Foulkes W.D., Knoppers B.M., Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. Nat Rev Clin Oncol 2016;13(1):41–54. doi: 10.1038/nrclinonc.2015.173
  5. Sultanbaev A.V., Nasretdinov A.F., Gordiev M.G. et al. Personalized approach in early diagnosis and prevention of malignant neoplasms. In: White Nights 2020. Abstracts of the VI Saint Petersburg International Cancer Forum. Saint Petersburg, 2020. P. 111. (In Russ.).
  6. Franceschini G., Di Leone A., Terribile D. et al. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know. Ann It Chir 2019;90:1, 2.
  7. Jakub J.W., Peled A.W., Gray R.J. et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg 2018;153(2):123–9. doi: 10.1001/jamasurg.2017.3422
  8. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Nat Cancer Inst 2009;101(2):80–7. doi: 10.1093/jnci/djn442
  9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
  10. Paluch-Shimon S., Cardoso F., Sessa C. et al. ESMO clinical Practice Guidelines for cancer prevention and screening in BRCA mutation carriers. Ann Oncol 2016;27:103–10.
  11. Claus E.B., Risch N., Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73(3):643–51. doi: 10.1002/1097-0142(19940201)73:3<643::aid-cncr2820730323>3.0.co;2-5
  12. Ford D., Easton D.F., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62(3):676–89. doi: 10.1086/301749
  13. Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. doi: 10.1086/375033. Erratum in: Am J Hum Genet 2003;73(3):709.
  14. Milne R.L., Osorio A., Cajal T.R. et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008;14(9):2861–9. doi: 10.1158/1078-0432.CCR-07-4436
  15. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25(11):1329–33. doi: 10.1200/JCO.2006.09.1066
  16. Brandt A., Lorenzo Bermejo J., Sundquist J. et al. Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start? Breast Cancer Res Treat 2010;121(1):133–41. doi: 10.1007/s10549-009-0486-y
  17. Peto J., Mack T.M. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000;26(4): 411–4. doi: 10.1038/82533
  18. Panchal S., Bordeleau L., Poll A. et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet 2010;77(3):273–9. doi: 10.1111/j.1399-0004.2009.01328.x
  19. Elmore J.G., Barton M.B., Moceri V.M. et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338(16):1089–96. doi: 10.1056/NEJM199804163381601
  20. Saslow D., Boetes C., Burke W. et al. American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57(2):75–89. doi: 10.3322/canjclin.57.2.75. Erratum in: CA Cancer J Clin 2007;57(3):185.
  21. Lee C.H., Dershaw D.D., Kopans D. et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010;7(1):18–27. doi: 10.1016/j.jacr.2009.09.022
  22. Mann R.M., Kuhl C.K., Kinkel K. et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 2008;18(7):1307–18. doi: 10.1007/s00330-008-0863-7
  23. Lee K., Seifert B.A., Shimelis H. et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med 2019;21(7):1497–506. doi: 10.1038/s41436-018-0361-5
  24. Melchor L., Benitez J. The complex genetic landscape of familial breast cancer. Hum Genet 2013;132(8):845–63. doi: 10.1007/s00439-013-1299-y
  25. Gabai-Kapara E., Lahad A., Kaufman B. et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA 2014;111(39):14205–10. doi: 10.1073/pnas.1415979111
  26. Breast Cancer Association Consortium, Dorling L., Carvalho S. et al. Breast cancer risk genes – association analysis in more than 113,000 women. N Engl J Med 2021;384(5):428–39. doi: 10.1056/NEJMoa1913948
  27. Hu C., Hart S.N., Gnanaolivu R. et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med 2021;384(5):440–51. doi: 10.1056/NEJMoa2005936
  28. Norquist B.M., Harrell M.I., Brady M.F. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2(4):482–90. doi: 10.1001/jamaoncol.2015.5495
  29. Hettipathirana T., Macdonald C., Xie J. et al. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations. Med J Aust 2021;215(10):460–4. doi: 10.5694/mja2.51226
  30. Boyd N.F., Guo H., Martin L.J. et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356(3):227–36. doi: 10.1056/NEJMoa062790
  31. Mann R.M., Kuhl C.K., Moy L. Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging 2019;50(2):377–90. doi: 10.1002/jmri.26654
  32. Gao Y., Reig B., Heacock L. et al. Magnetic resonance imaging in screening of breast cancer. Radiol Clin North Am 2021;59(1):85–98. doi: 10.1016/j.rcl.2020.09.004
  33. Guindalini R.S.C., Zheng Y., Abe H. et al. Intensive surveillance with biannual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1. Clin Cancer Res 2019;25(6):1786–94. doi: 10.1158/1078-0432.CCR-18-0200
  34. Bleyer A., Welch H.G. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367(21):1998–2005. doi: 10.1056/NEJMoa1206809
  35. Van Luijt P.A., Heijnsdijk E.A., Fracheboud J. et al. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res 2016;18(1):47. doi: 10.1186/s13058-016-0705-5
  36. Kuhl C., Weigel S., Schrading S. et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010;28(9):1450–7. doi: 10.1200/JCO.2009.23.0839
  37. Riedl C.C., Luft N., Bernhart C. et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 2015;33(10):1128–35. doi: 10.1200/JCO.2014.56.8626
  38. Vreemann S., van Zelst J.C.M., Schlooz-Vries M. et al. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. Breast Cancer Res 2018;20(1):84. doi: 10.1186/s13058-018-1019-6
  39. Phi X.A., Saadatmand S., De Bock G.H. et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer 2016;114(6):631–7. doi: 10.1038/bjc.2016.32
  40. Lee C.S., Monticciolo D.L., Moy L. Screening guidelines update for average-risk and high-risk women. AJR Am J Roentgenol 2020;214(2):316–23. doi: 10.2214/AJR.19.22205
  41. Hadar T., Mor P., Amit G. et al. Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer. JAMA Oncol 2020;6(9):1460–3. doi: 10.1001/jamaoncol.2020.2059
  42. European Commission Initiative on Breast Cancer. Planning Surgical Treatment. Available at: https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/surgical-planning.
  43. Tilanus-Linthorst M.M., Lingsma H.F., Evans D.G. et al. Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. Int J Cancer 2013;133(1):156–63. doi: 10.1002/ijc.28014
  44. Sardanelli F., Boetes C., Borisch B. et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010;46(8):1296–316. doi: 10.1016/j.ejca.2010.02.015
  45. Lehman C.D., Smith R.A. The role of MRI in breast cancer screening. J Natl Compr Canc Netw 2009;7(10):1109–15. doi: 10.6004/jnccn.2009.0072. Erratum in: J Natl Compr Canc Netw 2010;8(1):XXI.
  46. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 8.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
  47. Sultanbaev A.V., Lipatov O., Sultanbaeva N. et al. Germinal mutations landscape, which is responsible for cancer predisposition in multinational Republic of Bashkortostan. J Clin Oncol 2021;39 (15 Suppl):e22504. doi: 10.1200/JCO.2021.39.15_suppl.e22504
  48. Sultanbaev A.V., Menshikov K., Nasretdinov A. et al. Local features of germinal mutations incidence in cancer patients in the Republic of Bashkortostan. Ann Oncol 2021;32(15 Suppl):S1367. doi: 10.1016/j.annonc.2021.08.2066
  49. Sultanbaev A.V., Menshikov K., Musin S. et al. Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage. Ann Oncol 2022;33(9 Suppl):eS1511. doi: 10.1016/j.annonc.2022.10.229

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.